iAnthus Capital Competitors

iAnthus Capital (OTCMKTS:ITHUF) and Abacus Health Products (OTCMKTS:ABAHF) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, risk and profitability.

Earnings & Valuation

This table compares iAnthus Capital and Abacus Health Products' top-line revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of recent ratings and target prices for iAnthus Capital and Abacus Health Products, as reported by MarketBeat.com.

Profitability

This table compares iAnthus Capital and Abacus Health Products' net margins, return on equity and return on assets.

iAnthus Capital (OTCMKTS:ITHUF) and Acreage (OTCMKTS:ACRGF) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, risk and profitability.

Earnings & Valuation

This table compares iAnthus Capital and Acreage's top-line revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of recent ratings and target prices for iAnthus Capital and Acreage, as reported by MarketBeat.com.

Acreage has a consensus price target of $8.4333, indicating a potential upside of 204.45%. Given Acreage's higher possible upside, analysts clearly believe Acreage is more favorable than iAnthus Capital.

Profitability

This table compares iAnthus Capital and Acreage's net margins, return on equity and return on assets.

Summary

Acreage beats iAnthus Capital on 2 of the 2 factors compared between the two stocks.

iAnthus Capital (OTCMKTS:ITHUF) and Applied Biosciences (OTCMKTS:APPB) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, risk and profitability.

Earnings & Valuation

This table compares iAnthus Capital and Applied Biosciences' top-line revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of recent ratings and target prices for iAnthus Capital and Applied Biosciences, as reported by MarketBeat.com.

Profitability

This table compares iAnthus Capital and Applied Biosciences' net margins, return on equity and return on assets.

iAnthus Capital (OTCMKTS:ITHUF) and Ayr Strategies (OTCMKTS:AYRSF) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, risk and profitability.

Earnings & Valuation

This table compares iAnthus Capital and Ayr Strategies' top-line revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of recent ratings and target prices for iAnthus Capital and Ayr Strategies, as reported by MarketBeat.com.

Ayr Strategies has a consensus price target of $34.8571, indicating a potential upside of 63.96%. Given Ayr Strategies' higher possible upside, analysts clearly believe Ayr Strategies is more favorable than iAnthus Capital.

Profitability

This table compares iAnthus Capital and Ayr Strategies' net margins, return on equity and return on assets.

Summary

Ayr Strategies beats iAnthus Capital on 2 of the 2 factors compared between the two stocks.

iAnthus Capital (OTCMKTS:ITHUF) and Can B (NASDAQ:CANB) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, risk and profitability.

Earnings & Valuation

This table compares iAnthus Capital and Can B's top-line revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of recent ratings and target prices for iAnthus Capital and Can B, as reported by MarketBeat.com.

Profitability

This table compares iAnthus Capital and Can B's net margins, return on equity and return on assets.

iAnthus Capital (OTCMKTS:ITHUF) and Cansortium (OTCMKTS:CNTMF) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, risk and profitability.

Profitability

This table compares iAnthus Capital and Cansortium's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and target prices for iAnthus Capital and Cansortium, as reported by MarketBeat.com.

Cansortium has a consensus price target of $1.20, indicating a potential upside of 43.13%. Given Cansortium's higher possible upside, analysts clearly believe Cansortium is more favorable than iAnthus Capital.

Earnings & Valuation

This table compares iAnthus Capital and Cansortium's top-line revenue, earnings per share and valuation.

Summary

Cansortium beats iAnthus Capital on 2 of the 2 factors compared between the two stocks.